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Background: We previously reported a progressive decline in absolute responses of FEV1 and FVC to a near-maximal
dose of 2 different short-acting bronchodilators over 4 years. Since varying host factors and the method of expressing
the response may impact the time trend of acute bronchodilator responses, we now examined the potential influence of
salient host characteristics on changes in bronchodilator responses over time expressed in different ways.
Methods: As part of the 4-year, placebo-controlled Understanding Potential Long-term Impacts on Function with
Tiotropium (UPLIFT) trial, pre- and post-bronchodilator spirometry was performed at baseline and 1 month and
every 6 months thereafter. Post-bronchodilator values for FEV1 and FVC were analyzed for subjects completing
at least the 1 year visit (Placebo – N = 2463; Tiotropium – N = 2579), stratified by GOLD stage, age, gender and
smoking status and expressed as absolute, relative (%) and % predicted changes from pre-bronchodilator values.
Annual changes in bronchodilator response were estimated using linear mixed effects models.
Results: For all subjects analyzed, FEV1 and FVC bronchodilator responses showed progressive and highly
significant (p < 0.0001) declines over 4 years. Declines were generally larger in patients with severe/very severe
than mild/moderate airflow obstruction, in older patients (≥65 yrs) and in former than continuing smokers.
Conclusion: Acute FEV1 and FVC responses to bronchodilators decline significantly over time in COPD patients,
whether expressed as absolute, relative or % predicted changes, potentially impacting on the clinical responses
to bronchodilator therapy as well as on the annual rate of decline in post-bronchodilator lung function.
ClinicalTrials.gov number: NCT00144339
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Bronchodilator responsiveness is a well-described feature
of both asthma and COPD. While the response to a
bronchodilator in COPD is never complete, nonetheless
it often fulfills the currently accepted criteria for a sig-
nificant response [1–3], although the degree of response
(and the attainment of a significant response) is highly
variable between testing sessions [4,5]. Since COPD is
usually a progressive disease characterized by a variably
accelerated annual rate of decline in lung function, as* Correspondence: dtashkin@mednet.ucla.edu
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unless otherwise stated.determined from measurements of both pre- and post-
bronchodilator forced expired volume in 1 sec (FEV1)
[6], it is possible that the response to a bronchodilator
might also change over an extended period of time;
however, few studies have examined the long-term
course of responses to a bronchodilator in COPD with
varying results [7–9].
We recently compared the annual rates of change in
the pre- versus post-bronchodilator FEV1 and FVC over
4 years in 5041 COPD UPLIFT trial participants [10]
and observed that, on average, the absolute FEV1 and
forced vital capacity (FVC) responses to a bronchodila-
tor decreased progressively and significantly over the 4-
year course of the trial, in contrast to findings fromLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics of subjects in the placebo
and tiotropium arms of the UPLIFT trial included in the
analysis of time trends in bronchodilator responses over





Age, yrs, mean (SD) 64.2 (8.39) 64.3 (8.39)
>65 yrs, N (%) 1158 (47.0%) 1223 (47.4%)
≤65 yrs, N (%) 1305 (53.0%) 1356 (52.6%)
Gender, male, N (%) 1852 (75.2%) 1965 (76.2%)
Pre-bronchodilator FEV1, L, mean (SD) 1.12 (0.40) 1.11 (0.40)
Pre-bronchodilator FEV1, % predicted,
mean (SD)
39.9 (11. 8) 39.8 (11.9)
Post-bronchodilator FEV1, L, mean (SD) 1.35 (0.44) 1.34 (0.43)
Post-bronchodilator FEV1, % predicted,
mean (SD)
48.2 (12.4) 48.1 (12.5)
Pre-bronchodilator FVC, L, mean (SD) 2.66 (0.83) 2.64 (0.80)
Pre-bronchodilator FVC, % predicted,
mean (SD)
75.4 (18.0) 74.8 (17.9)
Post-bronchodilator FVC, L, mean (SD) 3.13 (0.90) 3.11 (0.86)
Post-bronchodilator FVC, % predicted,
mean (SD)
88.7 (18.7) 88.2 (18.5)
Pre-bronchodilator FEV1/FVC ratio, %,
mean (SD)
42.5 (10.3) 42.7 (10.4)
Post-bronchodilator FEV1/FVC ratio, %,
mean (SD)
43.8 (10.5) 43.9 (10.7)
Smoking status
Sustained ex-smoker, N (%) 1471 (59.7%) 1502 (58.2%)
Intermittent smoker, N (%) 679 (27.6%) 761 (29.5%)
Continuing smoker, N (%) 313 (12.7%) 316 (12.3%)
Pack-yrs smoking, mean (SD) 48.0 (27.9) 49.0 (28.0)
GOLD grade of airflow obstruction
Grade I/II, N (%) 1179 (48.6%) 1226 (48.3%)
Grade III, N (%) 1059 (43.6%) 1118 (44.0%)
Grade IV, N (%) 189 (7.79%) 197 (7.75%)
Use of Inhaled Corticosteroids at baseline
Yes 1506 (61.1%) 1581 (61.3%)
No 957 (38.9%) 998 (38.7%)
SGRQ total scores, mean (SD) 45.2 (17.2) 45.0 (17.0)
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no change, small average changes of varying significance
or substantial increases in responses were observed
[7-9]. These differences could be due to several factors,
including differences in the study populations, especially
regarding the severity of airflow obstruction, as well as
differences in the methods used to measure the bron-
chodilator response. Such methods included a standard
therapeutic dose of a beta-agonist followed only 10 mi-
nutes later by repeat spirometry in the IPPB trial [7] and
the Lung Health Study [8] and 400 mcg salbutamol with
repeat spirometry after only 15 minutes in the Evaluation
of COPD Longitudinally to Identify Predictive Surrograte
Endpoints (ECLIPSE) study [9], compared to double doses
of both a beta-agonist and a muscarinic antagonist and per-
formance of the post-bronchodilator spirometry at the ex-
pected time of peak or near-peak action of each of the two
classes of bronchodilators in the UPLIFT trial [11]. It is not
unlikely, therefore, that the responses to a bronchodilator
were sub-maximal in the earlier trials and near-maximal in
the UPLIFT study.
Because of these differences in methodology for meas-
uring the response to a bronchodilator and the possibil-
ity that varying host factors (including gender, age,
severity of airflow obstruction, smoking status and use
of inhaled corticosteroids) may impact the bronchodila-
tor response over time, we extended our analysis of the
time trend of bronchodilator responses (for both FEV1
and FVC) over the 4 years of the UPLIFT trial to exam-
ine the potential influence of these host factors on the
changes over time in bronchodilator responses expressed
in three different ways: absolute change in ml, percent
change from baseline and change in percent predicted.
Methods
We performed a post-hoc analysis of data from the UPLIFT
trial in which 5993 patients with moderate to very severe
COPD (mean age 65±8 yrs; mean post-bronchodilator
FEV1 1.32±0.44 L, 48% predicted) were randomized to re-
ceive tiotropium 18 mcg Handihaler once daily vs. placebo
over a 4-year period. Detailed methods and the main results
of UPLIFT have been published previously [11,12]. Briefly,
as part of this trial, pre- and post-bronchodilator spirometry
was performed in accordance with American Thoracic So-
ciety guidelines [13] at baseline and 1 month and every
6 months following randomization over 4 years. Identical
spirometric equipment and study-specific software were
used at each site with central quality-assurance review of all
spirometry data throughout the trial [12,14]. At each visit,
immediately following the pre-bronchodilator spirometry,
patients received study drug (either tiotropium or placebo)
followed by 4 inhalations of ipratropium, 18 μg/inhalation,
followed 1 hour later by 4 inhalations of albuterol, 100 μg/
inhalation, followed 30 min later by spirometry again. Ateach spirometry visit beginning at the baseline visit, study
drug was also administered immediately following the pre-
bronchodilator measurement. Prior to each spirometry
visit, patients were instructed to withhold their respiratory
medications for an appropriate period (Additional file 1).
Visits were postponed if patients experienced an exacerba-
tion within the preceding 6 weeks. The original UPLIFT
trial protocol had been approved by the ethics committee
at each center, and all patients had provided written in-
formed consent. UPLIFT was a global trial involving 37
countries and 490 investigational centers. The trial was
Figure 1 Mean absolute bronchodilator responses (±SD) (Δ = post- minus pre-bronchodilator FEV1 and FVC, ml) over 4 years by
treatment group separately (placebo and tiotropium). Mean absolute FEV1 responses are shown for the placebo group (A) and the
tiotropium group (B) separately. Mean absolute FVC responses are shown for the placebo group (C) and the tiotropium group (D) separately.
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each of the participating centers.
Analytic methods
Acute bronchodilator responses for both FEV1 and FVC
were expressed as absolute (ml), relative (%) and % pre-
dicted changes from the pre-bronchodilator values.
Since we noted a substantial decline in the absolute re-
sponse in the tiotropium group between the baseline
and 1-month assessment, responses were analyzed be-
ginning at the 1-month assessment for patients who
completed at least the 1-year post-randomization visit
(N = 2463 placebo and 2579 tiotropium patients) over
the 4 years of the trial. Since tiotropium resulted in a
sustained increase in the pre-bronchodilator FEV1
(which could have impacted on the response to the two
short-acting bronchodilators) and was administered
along with the latter to assess the acute bronchodilator
response in patients in the tiotropium arm of the trial,
data from the placebo and tiotropium treatment groups
were analyzed separately. Responses were also stratified
by GOLD grading for airflow obstruction (grades I/II, III
and IV), age (≤65 yrs, >65 yrs; median age was 65 yrs),
gender. smoking status (continuing smokers, sustainedformer smokers, intermittent smokers) and use of in-
haled corticosteroids (ICS) at baseline. Longitudinal ana-
lysis was conducted to estimate the annual changes in
bronchodilator response over the period from the 1-
month assessment to the end of the four-year follow-up.
In particular, the analysis was performed using linear
mixed effects models which included the subject-specific
trajectories and data clustering due to repeated measures
within patients. A linear time trend was assumed to de-
scribe the trajectory of bronchodilator response over the
4 year study period. The linearity assumption was tested
by including a quadratic time effect, but it was not sig-
nificant in the models. As an output of the model, the
annual change was expressed as the estimated fixed ef-
fect of time (in years) and the standard error of this re-
gression coefficient. Since this quantity was estimated
based on a statistical model, not raw data, its estimated
variability could only be expressed as standard error, not
standard deviation.
Because of the possibility that changes in bronchodila-
tor response over time within individual patients might
influence the change in their health-related quality of
life, we also examined, at the patient level, the relation-
ship between decline in bronchodilator response and
Table 2 Estimated average change per year over 4 years
in absolute bronchodilator response (Δ, in ml) (±SE) for
FEV1 and FVC in the placebo arm of the UPLIFT trial by
GOLD grading for airflow obstruction (I&II, III, IV), age
(≤50 yrs, >50 yrs), gender, and smoking status (sustained









All -10.9 (0.76) <0.0001 -20.6 (1.87) <0.0001
GOLD Stage
I & II -11.1 (1.10) <0.0001 -14.4 (2.42)1 <0.0001
III -11.2 (1.10) <0.0001 -25.2 (3.08) <0.0001
IV -13.1 (2.35) <0.0001 -40.6 (8.21) <0.0001
Age, yrs
≤65 yrs -11.6 (1.05) <0.0001 -15.5 (2.64)2 <0.001
>65 yrs -10.1 (1.09) <0.0001 -2.66 (2.60) <0.0001
Gender
Male -10.7 (0.92) <0.0001 -21.4 (2.27) <0.0001
Female -11.5 (1.21) <0.0001 -18.4 (2.98) <0.0001
Smoking status
Sustained ex-smoker -11.9 (0.93) 3 <0.0001 -24.6 (2.37)3 <0.0001
Intermittent smoker -10.5 (1.48) <0.0001 -17.3 (3.57) <0.0001
Continuing smoker -6.77 (2.42) 0.0053 -9.17 (5.70) 0.11
Inhaled steroids
(baseline)
No -8.41 (1.24)4 <0.0001 -11.3 (3.01)4 0.0002
Yes -12.5 (0.95) <0.0001 -26.6 (2.38) <0.0001
1Significantly different from GOLD III (p = 0.0059) and GOLD IV (p = 0.0006).
2Significantly different from age >65 yrs (pp = 0.0022).
3Signficiantly different from continuing smokers (p = 0.0264 for FEV1 and
p = 0.0088 for FVC).
4Significantly different from those with baseline inhaled steroids (p = 0.0081
for FEV1 and p < 0.0001 for FVC)).
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(SGRQ) total score over the course of the study in the
placebo group using a linear regression model. The
outcome was change in SGRQ total score at the end of
the study as compared to the baseline and the primary
predictor was the patient level change in bronchodila-
tor response per year estimated from the linear mixed
effects model, adjusting for baseline % predicted FEV1
and frequency of exacerbations in the first year (> = 2
versus < 2).
Within-patient variability was expressed as the
square-root of the variance for the regression residuals
estimated from the linear mixed effects models, and
between- patient variability in annual changes was
expressed as the square-root of the variance of the
slopes. Proportions of patients with a significant posi-
tive response according to ATS/ERS criteria [1],
namely an increase of FEV1 and/or FVC of 12% and
200 ml above baseline, were determined at each visit
and the odds ratios for annual changes in these proportions
were estimated using generalized estimating equations.
Results
Baseline clinical characteristics of the subjects included
in the analysis are shown in Table 1 for the placebo and
tiotropium groups separately. These are similar to those
in the entire UPLIFT population, as previously reported
[11]. Mean absolute FEV1 and FVC responses to the
bronchodilators (in ml ± SD) are shown for all patients,
in the placebo and tiotropium groups separately, at each
time point over the 4 years of the study in Figure 1. Pro-
gressive declines in both FEV1 and FVC responses are
observed beginning 1 to 1½ years after the start of the
study in both treatment groups.
Table 2 shows the estimated average change per year
over 4 years in the absolute bronchodilator response (Δ,
in ml) (±SE) for FEV1 and FVC in the placebo arm both
for all subjects and by GOLD grading for airflow ob-
struction, age, gender, smoking status and baseline ICS
use. The estimated changes per year in FEV1 and FVC
responses were significant for all subgroups, except
for changes in FVC responses among the continuing
smokers. The annual changes in the absolute FEV1 re-
sponse were larger for sustained ex-smokers than con-
tinuing smokers (p = 0.0264) and for those receiving ICS
at baseline (p = 0.0081) but did not differ significantly by
GOLD grade of airflow obstruction, age or gender. The
changes per year in FVC responses were significantly
larger in GOLD III and IV compared to GOLD I/II
(p = 0.0059 and 0.0006, respectively), in subjects >65
vs ≤ 65 yrs of age (0.0022), in sustained ex-smokers than
continuing smokers (p = 0.0088), and in those receiving
versus not receiving ICS at baseline (p < 0.0001). Similar
data are shown in Additional file 2 for the tiotropiumtreatment group. For all subjects analyzed, results were
comparable to those in the placebo group, although dif-
ferences were noted in some of the subgroups.
The time trends of relative bronchodilator responses
expressed as percent changes in FEV1 and FVC from
the pre-bronchodilator values are shown for all subjects
in each treatment group in Figure 2. Similar to the find-
ings for absolute changes, the percent changes in both
FEV1 and FVC declined progressively over 4 years,
beginning at 1 to 1.5 years after trial initiation for all
subjects in both treatment groups. Estimated average
changes per year in relative bronchodilator responses for
FEV1 and FVC (% ± SE) in all subjects and by GOLD
stage, age, gender, smoking status and baseline ICS use are
shown in Table 3 for the placebo group and Additional
file 3 for tiotropium subjects. In placebo subjects, declines
in both FEV1 and FVC responses were significantly greater
Figure 2 Mean percent changes (±SD) (Δ = post - minus pre-bronchodilator FEV1 and FVC, ml/pre-bronchodilator FEV1 and FVC, ml *
100, %) over 4 years by treatment group. Mean relative FEV1 responses (percent changes) are shown for the placebo group (A) and the tiotropium
group (B) separately. Mean relative responses (percent changes) in FVC are shown for the placebo group (C) and the tiotropium group (D) separately.
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tained ex-smokers than continuing smokers and in
those using ICS at baseline but did not differ by age or
gender, except for significantly greater declines in
FVC responses in older subjects. Similar findings were
noted in tiotropium subjects.
FEV1 and FVC responses to the bronchodilators
expressed as % predicted values over 4 years are shown
for all patients in each treatment group at each time
point in Figure 3. As with the other methods of express-
ing the bronchodilator response, a progressive decline in
% predicted responses for both FEV1 and FVC over
4 years was observed in both treatment groups. Esti-
mated average changes per year in % predicted responses
for FEV1 and FVC for all subjects and by subgroups are
shown in Table 4 for placebo subjects and Additional file
4 for tiotropium subjects. For all subjects in both treat-
ment groups annual declines were modest but highly
significant (p < 0.0001). In placebo subjects, declines in
percent predicted FVC responses were significantly lar-
ger in GOLD IV and GOLD III than GOLD I/II subjects
(p = 0.0013 and 0.0023, respectively) and in older than
younger patients (p = 0.0040), declines in % predicted
FEV1 responses were significantly larger in women than
men (p < 0.05) and declines in both FEV1 and FVC %predicted responses were significantly greater in sus-
tained ex-smokers than continuing smokers (p = 0.0267
and 0.0038, respectively), and in those on ICS at baseline
(p = 0.0045 and p < 0.0001, respectively). Somewhat com-
parable findings were noted in the tiotropium group
(Additional file 4).
A progressive decline was also observed in the propor-
tion of subjects in each treatment arm who fulfilled
ATS/ERS criteria for a significant bronchodilator re-
sponse, averaging 6-9% reduction in the proportion of
subjects likely to exhibit a significant bronchodilator re-
sponse per year (Table 5).
Findings from the analysis of the relationship between in-
dividual declines in bronchodilator response and individual
changes in health-related quality of life (assessed as total
SGRQ score) over the course of the study in the placebo
group indicated a modest but statistically significant inverse
relationship between decline in FEV1 (but not FVC) re-
sponse and change in SGRQ score, after adjustment for
both baseline FEV1 % predicted and exacerbation fre-
quency (≥2 versus <2) in the first year. For for each 1 ml
decline in FEV1 response there was an estimated 0.12 unit
increase in total SGRQ score (or for each 10 ml decline in
FEV1 response there was an estimated 1.2 unit increase in
SGRQ score) (data not shown).
Table 3 Estimated average change per year over 4 years
in relative bronchodilator response (percent change
Δ = post- minus pre-bronchodilator FEV1 and FVC/
pre-bronchodilator value X 100) (±SE) in the placebo
arm by GOLD grading for airflow obstruction (I&II, III,
IV), age (≤50 yrs, >50 yrs), gender, and smoking












All -0.68 (0.08) <0.0001 -0.66 (0.09) <0.0001
GOLD Stage
I & II -0.40 (0.11)1 0.0001 -0.28 (0.10)1 0.0085
III -0.86 (0.14)2 <0.0001 -0.89 (0.15)2 <0.0001
IV -2.08 (0.38) <0.0001 -2.11 (0.47) <0.0001
Age, yrs
≤65 yrs -0.61 (0.11) <0.0001 -0.34 (0.12)3 0.0058
>65 yrs -0.77 (0.12) <0.0001 -1.04 (0.13) <0.0001
Gender
Male -0.61 (0.10) <0.0001 -0.64 (0.10) <0.0001
Female -0.90 (0.17) <0.0001 -0.74 (0.19) <0.0001
Smoking status
Sustained ex-smoker -0.91 (0.11)4 <0.0001 -0.88 (0.11)3 <0.0001
Intermittent smoker -0.54 (0.16) 0.0007 -0.55 (0.17) 0.0014
Continuing smoker 0.12 (0.25) 0.64 0.14 (0.26) 0.59
Inhaled steroids
(baseline)
No -0.30 (0.13)5 0.0273 -0.13 (0.14)5 0.35
Yes -0.93 (0.11) <0.0001 1.01 (0.12) <0.0001
1Significantly different from GOLD III (p = 0.0072 for FEV1 and p = 0.0008 for
FVC) and GOLD IV (p < 0.0001 for FEV1 and p < 0.0001 for FVC).
2Significantly different from GOLD IV (p = 0.0018 for FEV1 and p = 0.0058
for FVC).
3Significantly different from age >65 (p < 0.0001).
4Signficiantly different from continuing smokers (p < 0.0001 for FEV1 and
p = 0.0002 for FVC).
5Significantly different from those with baseline inhaled steroids (p = 0.0002
for FEV1 and p < 0.0001 for FVC).
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change in absolute, relative and % predicted responses
over 4 years was quite large, as shown in Table 6 for
FEV1 and FVC and each treatment arm separately. No
significant differences were observed between treatment
groups. Variability in annual changes in FVC response
was approximately twice as large as that in FEV1 re-
sponses when expressed as absolute or % predicted
changes, but was similar when calculated as relative
changes.Discussion
We have shown that, in moderate to very severe COPD,
mean responses to a near-maximal bronchodilator chal-
lenge decline progressively over time to a statistically
significant, albeit modest and highly variable, extent, ir-
respective of the method of calculating the responses
(absolute, relative or % predicted pre-post bronchodila-
tor change). These downward trends in bronchodilator
responses were observed in nearly all subgroups defined
by the initial severity of airflow obstruction, age, gender,
smoking status over the course of the study and use of
ICS at baseline. However, the magnitude of the decline
in responses for FEV1 or FVC differed significantly
within some of these subgroups; for example, declines
over time in absolute, relative and % predicted FEV1
and/or FVC responses were larger in patients with se-
vere and very severe vs. mild/moderate airflow, > vs. ≤65
years of age, in sustained ex-smokers than continuing
smokers and in patients receiving versus not receiving
ICS at baseline (Tables 2, 3 and 4). The declines in re-
sponses for FVC tended to be larger than those for
FEV1 when these were assessed as absolute changes, but
not as relative or percent predicted changes. While some
differences in the mean annual changes in FEV1 and
FVC responses were noted between the placebo and tio-
tropium arms of the trial, these differences were not sta-
tistically significant irrespective of the method of
expressing the bronchodilator response.
Responses to a bronchodilator in COPD patients are
well known to vary over a relatively short time frame
such that a large proportion of patients who respond sig-
nificantly to a bronchodilator challenge on one day fail
to do so on another day and vice versa over a relatively
short time frame [4,5,15]. On the other hand, long-term
trends in bronchodilator responses over more than one
year have infrequently been measured [7,8]. In the IPPB
trial, in which the average baseline pre-bronchodilator
FEV1 (36.1% predicted) was comparable to that in UP-
LIFT (39.4% predicted), the mean change in the relative
FEV1 response per year over 3 years (-0.58/yr) was simi-
lar to that which we observed in UPLIFT over 4 years
(-0.68/yr) but, unlike the present findings, was not sig-
nificantly different from zero [7]. On the other hand, the
change in % predicted FEV1 response over 3 years
(-0.36/yr) was both similar to that noted in the UPLIFT
population over 4 years (-0.33/yr) and also significantly
different from zero. The long-term change in absolute
responses in the IPPB trial was not reported.
In contrast, in the 5-year LHS, in which the mean
baseline pre-bronchodilator FEV1 (75.4% predicted) was
much higher than that in either the IPPB trial or UP-
LIFT, a substantial increase in responsiveness (assessed
as relative, absolute and % predicted responses) was
noted over the first year, with either a slight further
Figure 3 Mean (±SD) % predicted (Δ = post-bronchodilator [% predicted] - minus pre-bronchodilator [% predicted] FEV1 and FVC)
bronchodilator responses over 4 years by treatment group. Mean % predicted FEV1 responses are shown for the placebo group (A) and the
tiotropium group (B) separately. Mean percent predicted responses in FVC are shown for the placebo group (C) and the tiotropium group (D)
separately.
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stantial increases from year 5 to year 11, except for the
absence of any perceptible change only in absolute re-
sponses in sustained quitters over this time frame [8].
The reason for these disparate findings in the LHS com-
pared to both the IPPP study and UPLIFT is unclear but
might possibly be related to the much milder degree of
airflow obstruction in LHS participants compared to those
in the other two studies. The observation that the decline
in relative responses in UPLIFT was significantly greater
in patients with severe/very severe than mild/moderate
airflow obstruction seems consistent with this possible ex-
planation; however, even the subgroup of UPLIFT subjects
with mild/moderate obstruction showed highly significant
declines in both FEV1 and FVC responses, irrespective of
the method of expressing these responses.
In this analysis, as in previous reports [5,7–9], the re-
sponse to a bronchodilator has been shown to be highly
variable both between and within individuals. Moreover,
because of this variability and because responsiveness
has not been shown to be predictive of exacerbations or
mortality in ECLIPSE [9] or predict the long-term re-
sponse to a bronchodilator over 1 year [16,17], broncho-
dilator responsiveness has been considered to be anunreliable phenotype [9]. However, the progressive de-
cline in bronchodilator responses over time demon-
strated in UPLIFT, as well as in the IPPB trial, mirrors
to some extent the usually progressive, but admittedly
variable, decline in lung function characteristic of
COPD, suggesting that these two phenomena might be
inter-related. One can only speculate as to the mechanism
of the observed declines in bronchodilator responses over
time. One possible mechanism is a progressive increase in
the thickness of the walls of the small airways with progres-
sive increases in the severity of airflow obstruction, as re-
ported by Hogg et al. [18]; the resulting decreases in airway
wall compliance could diminish the effect of bronchodilator-
induced airway smooth muscle relaxation in increasing the
patency of the lumen. It is also possible that the age-related
loss of lung elastic recoil [19] that is most likely amplified in
patients with progressive emphysema could counteract drug-
induced bronchodilation and reduction in air-trapping by
increasing dynamic airway compression.
One clinical implication of the progressive decline in
bronchodilator responses over multiple years is that this
might result in a reduced effectiveness of bronchodilator
therapy on clinical outcomes in COPD as the disease
progresses over time, at least in some patients in view of
Table 4 Estimated average change per year over 4 years in
% predicted bronchodilator response (Δ = % predicted
post-bronchodilator minus % predicted pre-bronchodilator
FEV1 or FVC) (±SE) in the placebo arm by GOLD grading
for airflow obstruction (I&II, III, IV), age (≤50 yrs, >50 yrs),
gender, and smoking status (sustained ex-smoker,









All -0.33 (0.03) <0.0001 -0.53 (0.05) <0.0001
GOLD Stage
I & II -0.33 (0.04) <0.0001 -0.35 (0.07)1 <0.0001
III -0.35 (0.04) <0.0001 -0.68 (0.09) <0.0001
IV -0.41 (0.08) <0.0001 -1.05 (0.24) <0.0001
Age, yrs
≤65 yrs -0.33 (0.04) <0.0001 -0.39 (0.07)2 <0.0001
>65 yrs -0.32 (0.04) <0.0001 -0.69 (0.08) <0.0001
Gender
Male -0.30 (0.03)3 <0.0001 -0.51 (0.06) <0.0001
Female -0.43 (0.06) <0.0001 -0.61 (0.11) <0.0001
Smoking status
Sustained ex-smoker -0.37 (0.03)4 <0.0001 -0.65 (0.07)3 <0.0001
Intermittent smoker -0.31 (0.05) <0.0001 -0.46 (0.10) <0.0001
Continuing smoker -0.18 (0.08) 0.0322 -0.16 (0.15) 0.29
Inhaled steroids
(baseline)
No -0.23 (0.04)5 0.0273 -0.27 (0.09)6 0.0024
Yes -0.39 (0.03) <0.0001 -0.70 ((0.07) <0.0001
1Significantly different from GOLD III (p = 0.0023) and GOLD IV (p = 0.0013).
2Significantly different from no baseline inhaled steroids (p = 0.0040).
3Significantly different from women (p = 0.0428).
4Signficiantly different from continuing smokers (FEV1 p = 0.0267;
FVC p = 0.0038).
5Significantly different from no baseline inhaled steroids (p = 0.0045).
6Significantly different from no baseline inhaled steroids (p < 0.0001).
Table 5 Between- and within-subjects variability in the
annual change in bronchodilator response expressed as












15.2 15.3 30.2 44.5
Within-subject variability
(square-root of variance)
109.2 107.9 244.7 252.0
Response measured
by % change in
FEV (ml)
Response measured
by % change in
FVC (ml)





1.44 1.65 1.43 1.98
Within-subject variability
(square-root of variance)
11.3 12.0 11.0 12.4
Response measured
by absolute change
in FEV (% predicted)
Response measured
by absolute change
in FVC (% predicted)





0.55 0.54 0.89 1.26
Within-subject variability
(square-root of variance)
3.93 3.88 7.04 7.23
1The variations were estimated from the linear mixed effects models.
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http://respiratory-research.com/content/15/1/102the large inter-individual variability observed in the de-
cline in responsiveness. The finding of a modest but
statistically significant within-individual relationship
between declines in acute bronchodilator responses on
the one hand and worsening SGRQ scores on the other
suggests that decrements in the response to a broncho-
dilator over time might be associated with poorer
clinical outcomes, although this association does not
necessarily imply causality. Moreover, the only modest
changes in SGRQ score in association with declines in
bronchodilator response (1.2 unit increase in SGRQ
for each 10 ml decline in acute FEV1 response) argue
against a clinically meaningful relationship. Another
implication of our findings is that the decline in the
acute bronchodilator response over time would lead toa partial convergence of the slopes of decline in lung func-
tion calculated from the pre- and post-bronchodilator
FEV1 (and FVC), resulting in a steeper post- than pre-
bronchodilator slope [10]. Moreover, these potential
consequences are likely to be relatively independent of
the severity of airflow obstruction, age, gender and
smoking status since significantly progressive declines
in bronchodilator responses were seen in most of these
subgroups. The possible impact on the slope of change
in post- vs. pre-bronchodilator lung function over time
needs to be taken into account in the design of long-
term trials in which the annual decline in post-
bronchodilator lung function is measured as a means
of assessing the rate of progression of COPD.
The strengths of the present analysis include the
large number of patients with varying degrees of sever-
ity of airflow obstruction who were followed over an
extended period of time, the high quality and reprodu-
cibility of spirometry [14] and the relatively large doses
of the two different classes of short-acting bronchodi-
lators that were administered along with the timing of
Table 6 Long-term trends in the proportion of subjects in each treatment arm who achieved a significant
bronchodilator response for FEV1, FVC and either FEV1 or FVC
FEV FVC FEV or FVC
Tiotropium Placebo Tiotropium Placebo Tiotropium Placebo
Time N Proportion N Proportion N Proportion N Proportion N Proportion N Proportion
1 m 2535 0.42 2416 0.55 2535 0.47 2416 0.62 2535 0.59 2416 0.73
6 m 2515 0.42 2391 0.53 2515 0.44 2391 0.63 2515 0.57 2391 0.72
1 yr 2503 0.39 2382 0.53 2503 0.43 2382 0.63 2503 0.55 2382 0.72
1.5 yr 2380 0.40 2200 0.51 2380 0.43 2200 0.62 2380 0.56 2200 0.71
2 yr 2236 0.39 2040 0.49 2236 0.43 2040 0.60 2236 0.56 2040 0.69
2.5 yr 2132 0.39 1906 0.50 2132 0.42 1906 0.61 2132 0.55 1906 0.70
3 yr 2012 0.36 1792 0.47 2012 0.39 1792 0.59 2012 0.52 1792 0.69
3.5 yr 1894 0.36 1674 0.47 1894 0.41 1674 0.59 1894 0.52 1674 0.68
4 yr 1804 0.35 1599 0.47 1804 0.39 1599 0.56 1804 0.51 1599 0.66
Estimated OR (95% CI) for
change in proportion per
year*
0.92 (0.90, 0.94) 0.91 (0.89, 0.94) 0.93 (0.91, 0.95) 0.94 (0.92, 0.96) 0.92 (0.90, 0.94) 0.92 (0.90, 0.95)
p-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
*The OR (odds ratio) and its 95% CI were estimated with GEE methods using data starting from 1 m.
FEV: Tiotropium vs. placebo p = 0.79.
FVC: Tiotropium vs. placebo p = 0.60.
FEV or FVC: Tiotropium vs. placebo p = 0.84.
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http://respiratory-research.com/content/15/1/102post-bronchodilator spirometry to coincide with the time
of expected peak action of each class of bronchodilator.
A major limitation is the large drop-out rate with only
27%, 35% and 40% of subjects completing visits at 2, 3
and 3¾ yrs, respectively. The current analysis uses all
available data and the statistical inference from linear
mixed effects models is valid under the missing at ran-
dom assumption. Moreover, those who discontinued the
trial prematurely were more likely to have fared poorly
during the trial, suggesting that their bronchodilator re-
sponses, had they been measured subsequent to their
withdrawal, might tend to be even less robust than the
responses at later time points in those subjects who
completed the trial.
In conclusion, acute responses of both FEV1 and FVC
to near maximal doses of two different bronchodilators,
while considerably variable both between and within in-
dividuals, on average diminish progressively and signifi-
cantly over time, consistent with the usually progressive
decline in lung function with age in patients with COPD.
These declines were independent of the method of ex-
pressing the bronchodilator response and tended to be
larger in patients with severe/very severe compared to
those with mild/moderate airflow obstruction, in pa-
tients >65 years of age and in former than continuing
smokers and in those not on ICS at baseline. These
declines in the response to a bronchodilator imply a
possible diminution in the clinical efficacy of broncho-
dilator therapy over time and may account for differ-
ences in the slopes of lung function decline with agewhen calculated using the post- compared to the pre-
bronchodilator value.Additional files
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